451 related articles for article (PubMed ID: 30516990)
21. Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs.
Rawal RK; Murugesan V; Katti SB
Curr Med Chem; 2012; 19(31):5364-80. PubMed ID: 22998569
[TBL] [Abstract][Full Text] [Related]
22. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Farmaco; 1999; 54(1-2):26-45. PubMed ID: 10321027
[TBL] [Abstract][Full Text] [Related]
23. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
de Béthune MP
Antiviral Res; 2010 Jan; 85(1):75-90. PubMed ID: 19781578
[TBL] [Abstract][Full Text] [Related]
24. Rational Design of Doravirine: From Bench to Patients.
Hwang C; Lai MT; Hazuda D
ACS Infect Dis; 2020 Jan; 6(1):64-73. PubMed ID: 31621289
[TBL] [Abstract][Full Text] [Related]
25. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
[TBL] [Abstract][Full Text] [Related]
26. Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.
Famiglini V; Silvestri R
Molecules; 2016 Feb; 21(2):. PubMed ID: 26891289
[TBL] [Abstract][Full Text] [Related]
27. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
28. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
[TBL] [Abstract][Full Text] [Related]
29. The effect of NNRTIs on HIV reverse transcriptase dimerization.
Tachedjian G; Goff SP
Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
[TBL] [Abstract][Full Text] [Related]
30. Current insights and molecular docking studies of HIV-1 reverse transcriptase inhibitors.
Singh AK; Kumar A; Arora S; Kumar R; Verma A; Khalilullah H; Jaremko M; Emwas AH; Kumar P
Chem Biol Drug Des; 2024 Jan; 103(1):e14372. PubMed ID: 37817296
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
[TBL] [Abstract][Full Text] [Related]
32. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
Menéndez-Arias L; Betancor G; Matamoros T
Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
[TBL] [Abstract][Full Text] [Related]
34. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.
Sluis-Cremer N; Wainberg MA; Schinazi RF
Future Microbiol; 2015; 10(11):1773-82. PubMed ID: 26517190
[TBL] [Abstract][Full Text] [Related]
35. DPC-083. DuPont Pharmaceuticals.
Lim ML
Curr Opin Investig Drugs; 2001 Sep; 2(9):1209-12. PubMed ID: 11717806
[TBL] [Abstract][Full Text] [Related]
36. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
37. [Role of etravirine in combination antiretroviral therapy].
Domingo P
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
[TBL] [Abstract][Full Text] [Related]
38. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Silvestri R
Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
[TBL] [Abstract][Full Text] [Related]
39. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H;
Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492
[TBL] [Abstract][Full Text] [Related]
40. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections.
Pauwels R
Curr Opin Pharmacol; 2004 Oct; 4(5):437-46. PubMed ID: 15351347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
